State Street’s Structure Therapeutics GPCR Stock Holding History
Bought
Maintained
Sold
Other funds holding GPCR
BBA
State Street's GPCR Position: Q3 2026 in Review
State Street increased its Structure Therapeutics (GPCR) stake by 107% in Q3 2026, buying an estimated $2.25M and bringing the position to 92,556 shares worth $2.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3289.
State Street first reported a position in GPCR in Q2 2023 and has held it in 14 quarters since. The position peaked at $3.35M in Q4 2025. 172 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.
- State Street held 92,556 shares of Structure Therapeutics worth $2.89M as of Q3 2026.
- State Street bought 47,927 Structure Therapeutics shares in Q3 2026, an estimated $2.25M.
- Structure Therapeutics made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3289 holding.
- State Street first reported a position in Structure Therapeutics in Q2 2023 and has held it in 14 quarters since.
- State Street's Structure Therapeutics position peaked at $3.35M in Q4 2025.
- 172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.
Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.